EYEBIOTECH
Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
EYEBIOTECH
Social Links:
Industry:
Biotechnology Medical
Founded:
2021-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.eyebiotech.com
Total Employee:
11+
Status:
Active
Total Funding:
65 M USD
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail
Current Advisors List
Current Employees Featured
Investors List
SV Health Investors
SV Health Investors investment in Series A - Eyebiotech
MRL Ventures Fund
MRL Ventures Fund investment in Series A - Eyebiotech
Samsara BioCapital
Samsara BioCapital investment in Series A - Eyebiotech
Jeito Capital
Jeito Capital investment in Series A - Eyebiotech
SV Health Investors
SV Health Investors investment in Seed Round - Eyebiotech
Official Site Inspections
http://www.eyebiotech.com Semrush global rank: 3.32 M Semrush visits lastest month: 4.87 K
- Host name: 125.166.75.34.bc.googleusercontent.com
- IP address: 34.75.166.125
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Eyebiotech"
Home | EyeBio
EyeBio is a clinical-stage ophthalmology biotech company that brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for …See details»
Restoret - EyeBio
Restoret (EYE103) seeks to eliminate leakage in retinal vascular diseases by agonizing the Wnt pathway to both restore and maintain the blood retinal barrier (BRB). By actuating this mechanism, the drug may reduce leakage associated …See details»
EyeBio Announces Expansion of Series A to $130 Million, Advances ...
Nov 14, 2023 · EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining …See details»
Eyebiotech - Crunchbase Company Profile & Funding
Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases. Eyebiotech may be growing as evidenced by a significant acquisition deal and its …See details»
MSD Completes Acquisition of EyeBio
RAHWAY, N.J., July 12, 2024 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK) today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of MSD.See details»
MSD to Acquire EyeBio
May 29, 2024 · Eyebiotech Limited (EyeBio) is a clinical-stage, privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore and improve vision in patients …See details»
Merck Completes Acquisition of EyeBio - Business Wire
Jul 12, 2024 · RAHWAY, N.J.-- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition …See details»
Merck Completes Acquisition of EyeBio | EyeBio
RAHWAY, N.J., July 12, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited …See details»
Merck Completes Acquisition of EyeBio
Jul 12, 2024 · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition …See details»
Merck completes acquisition of EyeBio
Jul 15, 2024 · EyeBio is now a wholly-owned subsidiary of Merck. The deal is valued as high as $3 billion, including an upfont cash payment of $1.3 billion, along with the potential for an additional $1.7 billion in developmental, …See details»
Merck to acquire EyeBio for upfront payment of $1.3 …
May 31, 2024 · Merck and Eyebiotech Limited announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.See details»
Merck to Acquire EyeBio - Business Wire
May 29, 2024 · Eyebiotech Limited (EyeBio) is a clinical-stage, privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies …See details»
Merck to Buy Eye-Focused Drug Developer EyeBio for as Much as …
May 29, 2024 · (Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion, as it looks to diversify its portfolio of experimental drugs with treatments …See details»
EyeBiotech Limited Announces $130 Million Series A - Cooley
London – November 14, 2023 – Cooley advised EyeBiotech Limited (EyeBio), a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of …See details»
EyeBio Raises $65M in Series A Funding to Develop New …
Feb 22, 2022 · Eyebiotech Limited (EyeBio) is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, …See details»
Eyebiotech Company Profile - Office Locations, Competitors, …
Eyebiotech is a company, which helps to restore vision for people with eye diseases. It provides a technology that uses anti-vascular endothelial growth factor (anti-VEGF) therapy for patients …See details»
EyeBio Announces First Asset in Innovative Pipeline of Retinal …
Mar 6, 2023 · EyeBio co-founder Anthony P. Adamis, M.D., appointed chief scientific officer to lead development of the Company’s ophthalmology pipeline. Company provides details on …See details»
Merck to Acquire EyeBio - Merck.com
May 29, 2024 · Eyebiotech Limited (EyeBio) is a clinical-stage, privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies …See details»
Merck to buy EyeBio, maker of eye drug, as it grows pipeline - STAT
May 29, 2024 · L ONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.See details»
EyeBio Raises $65M in Series A Funding to Develop New …
Feb 22, 2022 · LONDON and NEW YORK, February 22, 2022 – Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of …See details»